1. Introduction
1.1 Executive Summary
1.2 Market Definition
1.3 Scope of the Study
2. Research Methodology
2.1 Secondary Research
2.2 Primary Research
2.3 Analytic Tools and Model
2.4 Economic Indicator
2.4.1 Base Year, Base Currency, Forecasting Period
2.5 Expert Validation
2.6 Study Timeline
3. Market Analysis
3.1 Industry Value Chain Analysis
3.2 Porter's Five Analysis
3.2.1 Bargaining Power of Buyers
3.2.2 Bargaining Power of Suppliers
3.2.3 Threats of Substitutes
3.2.4 Threats of New Entrants
3.2.5 Industry Rivalry
3.3 PESTLE Analysis
3.3.1 Political
3.3.2 Economical
3.3.3 Social
3.3.4 Technological
3.3.5 Legal
3.3.6 Environmental
3.4 SWOT Analysis
3.4.1 Strengths
3.4.2 Weakness
3.4.3 Opportunities
3.4.4 Threats
3.5 Y-O-Y Analyses
4. Market Dynamics
4.1 Drivers
4.1.1 Increasing incidences of chronic diseases
4.1.2 Rise in the number of clinical trials performed
4.1.3 Synchronization of Hospital Information System (HIS) with CTMS
4.1.4 Increase in R&D to implement localised research programs
4.2 Restraints
4.2.1 Huge cost of customised CTMS
4.2.2 Lack of qualified and skilled labour to handle CTMS
4.2.3 Data security issues
4.3 Opportunities
4.3.1 Increasing Personalized Medicines
4.4 Challenges
4.4.1 Increasing Complexity of Trials
4.4.2 High on maintenance and operational costs
5. Asia-Pacific Clinical Trials Market - By Phases
5.1 Phase I
5.2 Phase II
5.3 Phase III
5.4 Phase IV
6. Asia-Pacific Clinical Trials Market- By Design
6.1 Observational Studies
6.1.1 Cohort Study
6.1.1.1 Time-Series Cohort
6.1.1.2 Retrospective Cohort
6.1.1.3 Prospective Cohort
6.1.2 Ecological Study
6.1.3 Cross Control Study
6.1.4 Case-Control Study
6.2 Treatment Studies
6.2.1 Randomized Control Trial
6.2.1.1 Double-Blind Randomized Trial
6.2.1.2 Non-Blind Trial
6.2.1.3 Single Blind Randomized Trial
6.2.2 Non-Randomized Clinical Trial
6.2.3 Adaptive Clinical Trial
7. Asia-Pacific Clinical Trials Market- By Country
7.1.Introduction
7.2.Indi
7.3. China
7.4. Japan
7.5 South Korea
7.7 Rest of Asia-Pacific
8. Company Profiles
8.1 Paraxel
8.2 Accovion
8.3 Pharmnet
8.4 Quotient Bioresearch
8.5 ICON Plc
8.6 Chiltern
8.7 Omnicare
8.8 PPD
8.9 Kendle
8.10 Quintles
8.11 Charles River
9. Asia-Pacific Clinical Trials Market- Competitive Landscape
9.1 Market Share Analysis
9.2 Strategies Adopted by top companies
9.3 Mergers, Acquisitions, Collaborations & Agreements
10. Market Insights
10.1 Insights of Industry Experts
10.2 Investment Opportunities
10.3 Analyst Opinion
11. Appendix
11.1 List of Tables
11.2 List of Figures
